Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma
-CAR T cells without upregulating exhaustion markers (PD-1/LAG3). These findings suggest that in the management of treatment-resistant pediatric solid tumors, utilizing chidamide during the manufacturing of CRISPR-engineered CAR T cells may enhance their persistence while retaining a naive phenotype.
Authors
- Quaovi H. Sodji (ORCID: https://orcid.org/0000-0002-9469-1388)
- Dan Cappabianca (ORCID: https://orcid.org/0009-0005-2354-4363)
- Mahmoud Toulany (ORCID: https://orcid.org/0000-0002-8868-6523)
- Sean Foster (ORCID: https://orcid.org/0000-0001-7475-8509)
- José M. Ayuso (ORCID: https://orcid.org/0000-0002-9414-1845)
- Varun Gnanasekar (ORCID: https://orcid.org/0000-0001-8811-3787)
- Krishanu Saha (ORCID: https://orcid.org/0000-0003-2837-0858)
- Jolanta Vidugirienė
- Rithvik V. Turaga
- Seth Zima
- Anthony Lauer
- Kayla Sylvester
- Amanda Shea
Institutions
- University of Wisconsin–Madison (US)
- Promega (United States) (US)
- Wisconsin Institutes for Discovery (US)
- University of Wisconsin Carbone Cancer Center (US)
Publication Details
- Journal
- Molecular Therapy Oncology
- Published
- 2026-04-07
- DOI
- https://doi.org/10.1016/j.omton.2026.201200
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- School of Medicine and Public Health, University of Wisconsin-Madison